183 related articles for article (PubMed ID: 28085003)
1. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
Peres-da-Silva A; Brandão-Mello CE; Lampe E
Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
[TBL] [Abstract][Full Text] [Related]
3. Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.
Noble CF; Malta F; Lisboa-Neto G; Gomes-Gouvêa MS; Leite AGB; de Castro VFD; Santana RAF; Carrilho FJ; Mendes-Correa MC; Pinho JRR
Arch Virol; 2017 Jan; 162(1):165-169. PubMed ID: 27704215
[TBL] [Abstract][Full Text] [Related]
4. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
5. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
Wei L; Omata M; Lim YS; Xie Q; Hou JL; Jia J; Hedskog C; Martin R; Doehle B; Yang J; De-Oertel S; Massetto B; Kersey K; Brainard DM; Svarovskaia E; Mo H; Han KH; Mizokami M; Duan Z
Antiviral Res; 2018 Oct; 158():178-184. PubMed ID: 30120954
[TBL] [Abstract][Full Text] [Related]
6. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
[TBL] [Abstract][Full Text] [Related]
8. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
[TBL] [Abstract][Full Text] [Related]
10. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
[TBL] [Abstract][Full Text] [Related]
11. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
Svarovskaia ES; Gane E; Dvory-Sobol H; Martin R; Doehle B; Hedskog C; Jacobson IM; Nelson DR; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
J Infect Dis; 2016 Apr; 213(8):1240-7. PubMed ID: 26603202
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.
Yang S; Xing H; Feng S; Ju W; Liu S; Wang X; Ou W; Cheng J; Pan CQ
Arch Virol; 2018 Feb; 163(2):467-473. PubMed ID: 29143142
[TBL] [Abstract][Full Text] [Related]
13. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
[TBL] [Abstract][Full Text] [Related]
14. Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
Gaspareto KV; Ribeiro RM; de Mello Malta F; Gomes-Gouvêa MS; Muto NH; Romano CM; Mendes-Correa MC; Carrilho FJ; Sabino EC; Rebello Pinho JR
Antivir Ther; 2016; 21(8):653-660. PubMed ID: 27314166
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
Xu S; Doehle B; Rajyaguru S; Han B; Barauskas O; Feng J; Perry J; Dvory-Sobol H; Svarovskaia ES; Miller MD; Mo H
Antivir Ther; 2017; 22(7):587-597. PubMed ID: 28248189
[TBL] [Abstract][Full Text] [Related]
16. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
Donaldson EF; Harrington PR; O'Rear JJ; Naeger LK
Hepatology; 2015 Jan; 61(1):56-65. PubMed ID: 25123381
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
Karbalaie Niya MH; Salman-Tabar S; Bokharaei-Salim F; Behmanesh M; Keyvani H
Microb Pathog; 2017 Apr; 105():166-170. PubMed ID: 28161357
[TBL] [Abstract][Full Text] [Related]
18. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
[TBL] [Abstract][Full Text] [Related]
19. Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.
Younas S; Sumrin A; Hussain N; Bilal M
J Appl Microbiol; 2022 Nov; 133(5):2826-2834. PubMed ID: 35916643
[TBL] [Abstract][Full Text] [Related]
20. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]